EVGN
Evogene Ltd. (NASDAQ)
Healthcare — Biotechnology
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Price History
Fundamentals
| Market Cap | $5.34M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.55 |
| EPS (TTM) | $-1.70 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -86.30% |
| ROE | -171.75% |
| Debt/Equity | 25.42 |
| Recommendation | None |
| Analyst Target | $2.15 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 20.0 |
| Beta | 0.74 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1.50 |
| 52-Week Low | $0.37 |
| 50-Day Avg | $0.66 |
| 200-Day Avg | $0.95 |
| Avg Volume | $1.11M |
| Volume | 131.1K |
Performance Analysis
NEUTRALEVGN presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:08 UTC
Back to Screener Export Report